Taconic Capital Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Taconic Capital Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-46,500	Closed	-$470K	–	476
2022 Q4	$470K	Hold	46,500	–	–	0.01%	302
2022 Q3	$461K	Hold	46,500	–	–	0.01%	383
2022 Q2	$455K	Buy	+46,500	New	+$455K	0.01%	394

Taconic Capital Advisors's EBAC Position: Q1 2023 in Review

Taconic Capital Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 46,500 shares — an estimated $470K sold.

Taconic Capital Advisors first reported a position in EBAC in Q2 2022 and held it in 3 quarters. The position peaked at $470K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Taconic Capital Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Taconic Capital Advisors sold 46,500 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $470K.
Taconic Capital Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2022 and held it in 3 quarters.
Taconic Capital Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $470K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Taconic Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.